ObjectivesIn 2003, the World Health Organization (WHO) and Joint United Nations Programme on HIV/AIDS (UNAIDS) introduced the '3 by 5 Initiative' to treat 3 million individuals by the end of 2005. This study evaluates the time to treatment termination, viral load suppression, and detection of drug resistance among antiretroviral-naïve individuals initiating stavudine/lamivudine/nevirapine (d4T/3TC/NVP) in British Columbia, Canada, to provide a context for future programme planning.
MethodsPrimary outcome was time to treatment termination. Secondary outcome was time to viral suppression. Accumulation of drug resistance mutations was followed systematically in the first 145 individuals over 30 months. Cox proportional hazard regression identified factors associated with termination and suppression. 3), 132 (42.3%) patients switched treatment, 53 (17.0%) stopped therapy and 26 (8.3%) died. Of 308 subjects with baseline viral load 4500 copies/mL, 223 (72.4%) suppressed to 500 copies/mL at a median of 2.0 months. Among 145 (46.5%) individuals followed longitudinally, resistance mutations to NNRTI, 3TC, or other NRTI were detected in 11 (7.6%), six (4.1%) and four (2.8%) individuals after 12 months of therapy; and in 23 (15.9%), 17 (12.0%), and six (4.1%) individuals after 30 months.
ConclusionsThe population requiring second-line treatment was 30% at 12 months and 40% at 24 months; 20% had detectable drug resistance mutations by 30 months. While these results are from a Western setting, they illustrate the need to consider second-and third-line approaches as antiretroviral treatment scale-up continues in the developing world.Keywords: antiretroviral therapy, cohort studies, drug resistance, epidemiology, World Health Organization . The WHO plan recommended regimens consisting of lamivudine (3TC) with stavudine (d4T) or zidovudine (ZDV), and either nevirapine (NVP) or efavirenz (EFV) [2]. As a result of the availability of a simple fixed dose combination, the d4T/3TC/NVP regimen has become widely used. However, limited data are available regarding the use of this regimen in resource-limited settings.In order to provide a context for programme planning where access to technologies such as viral load and drug
Methods
BC Centre for Excellence in HIV/AIDS Drug Treatment ProgrammeIn the province of BC, antiretrovirals are distributed free of charge to HIV-1-infected individuals through a centralized HIV/AIDS drug treatment programme where a complete prospective profile of therapy use is maintained. Antiretrovirals are prescribed according to specific guidelines set by the British Columbia Therapeutic Guidelines Committee which are largely consistent with international guidelines [3].
Study populationAll HIV-1-positive, antiretroviral-naïve adults who initiated HAART with d4T/3TC/NVP in BC between 1 August 1996 and 30 September 2003 were eligible for inclusion in the study. Our analysis was restricted to individuals who had baseline CD4 and plasma viral load (pVL) data available within 6 months prior to the start of treat...